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Abstract
Background This study aimed to readjust the appraisal of
birdshot retinochoroiditis (BRC) in light of a global approach,
including the full array of investigational procedures.
Patients and methods This retrospective study reviewed
charts of BRC cases treated in the uveitis clinic of our center
between 1995 and 2011. We identified 25 patients with
BRC; of these, 19 had sufficient data for inclusion in the
study. Patients were examined with a standard clinical ap-
proach for inflammatory disorders, including dual fluores-
cence angiography with fluorescein and indocyanine green,
perimetry, and laser flare photometry, both at presentation
and during follow-up. Spectral optical coherence tomogra-
phy (OCT) was performed when available. Disease charac-
teristics and evolutionary patterns were reported.
Results Human leucocyte antigen was positive for the A29
allele in all patients. The mean age at presentation was
49.6±10.0 years, the mean diagnostic delay was 21.5±
18 months, and the mean follow-up was 85±60 months.
Out of 19 patients, three presented with mutton-fat
keratic precipitates (KPs), three had no depigmented
lesions at presentation, and eight did not fulfill the
recommended criterion of three depigmented peripapillar
lesions. Cystoid macular edema (CMO) at entry was
present in 8/19 cases. Perimetric anomalies were noted
in all patients at presentation. In 92 % of cases, fluo-
rescein findings included disc hyperfluorescence, retinal
vasculitis of large vessels, and leakage from medium-
sized and small vessels. In all patients, a (pseudo)-delay
was noted in the arterio-venous circulation time (mean venous
dye appearance 0 42.1±13.1 s), which reflected massive
capillary leakage. At presentation, all patients exhibited
indocyanine green angiographic signs, including hypo-
fluorescent dark dots, vessel fuzziness, and areas of diffuse
late hyperfluorescence. This allowed early diagnosis in
3/19 patients (16 %) without birdshot fundus lesions at
presentation.
Conclusions BRC is a granulomatous uveitis, and mutton-
fat KPs do not exclude the disease. When BRC is suspected,
indocyanine green angiography is crucial to allow early
diagnosis and to monitor the evolution of choroiditis. Peri-
metry is an obligate investigation for diagnosis and follow-
up. CMO is less frequent than stated earlier. Scores of
fluorescein and indocyanine green angiographic signs indi-
cated that choroiditis responded readily to therapy, but ret-
initis was relatively resistant to therapy.
Keywords Birdshot retinochoroiditis . Indocyanine green
angiography . Choroidal granuloma
Introduction
Birdshot retinochoroiditis (BRC) is an intraocular inflam-
matory condition, mostly observed in Caucasian popula-
tions. BRC is linked to the presence of the tissue
histocompatibility antigen HLA-A29, but without any
known systemic association [1, 2].
To date, the appraisal of BRC has mostly been only
partial and sometimes insufficient; this has given rise to
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several misconceptions of the disease. In most chorioretinal
inflammatory diseases, the inflammatory process takes place
in one structure, like the choroid in Vogt–Koyanagi–Harada
(VKH) disease, or the retina in toxoplasmosis. Then, it
extends to neighboring structures, as the inflammation
becomes more severe, such as the retina and the choroid.
In BRC, the pathogenesis of inflammation is unique; it
occurs independently, but simultaneously in the choroid
and the retina [3]. This concept has not been brought for-
ward clearly, despite the consequences it has on the
approaches for treating the disease. This dual, independent
involvement can explain why both fluorescein angiography
(FA) and indocyanine green angiography (ICGA) are nec-
essary for correct assessments of intraocular inflammatory
involvement, and why the kinetics of inflammation should
be followed in both compartments. Unfortunately, routine
ICGA, even in conditions with known predominant choroi-
dal involvement, is still not performed routinely. For mon-
itoring disease progression, visual field (VF) testing is
crucial in BRC. Despite the fact that this has been stressed
for over 10 years [4], only more recently have studies dealt
with this aspect of the disease [5, 6]. Moreover, in current,
routine uveitis practice, VF testing is still not acknowledged
as the most relevant functional test to monitor disease pro-
gression or response to therapy, and VF testing is rarely
described in studies on BRC.
The consequence of misunderstanding BRC was illus-
trated in the publication of international research diagnostic
criteria (IRDC) for BRC; among other inadequacies, the
IRDC did not even mention VF testing or ICGA [7]. In
the present study, we investigated and followed a series of
19 patients with BRC. We used a comprehensive approach,
including analysis of choroidal involvement, optical coher-
ence tomography (OCT) analysis of retinal involvement,
laser flare photometric analysis of anterior chamber involve-
ment, and visual field status. We aimed to address several
misconceptions about BRC and provide a global overview
of the disease.
Materials and methods
We retrospectively reviewed charts of patients examined in
the uveitis clinic at the Center for Ophthalmic Specialized
Care, Lausanne, Switzerland between 1995 and 2010.
Patients with a BRC diagnosis were identified. Diagnostic
criteria included vitreitis and retinal vasculitis in either or
both eyes, visual field loss in either or both eyes, stromal
choroiditis in both eyes evidenced by ICGA, and the pres-
ence of the HLA-A29 antigen. An additional, but not obliga-
tory criterion was the presence of rice-shaped, depigmented
“birdshot lesions”. All patients underwent the complete work-
up routinely applied to patients with posterior uveitis. Routine
examinations included the Snellen visual acuity test, slit-lamp
examination, applanation tonometry, and funduscopy in my-
driasis. In addition, at each major visit, a complete ocular
examination was performed that comprised laser flare pho-
tometry, computerized VF testing, OCT (when available), and
dual FA and ICGA.
The study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
FA and ICGA were performed with a standard protocol
described previously [8]. Typically, FA and ICGA were
performed simultaneously. Images were acquired with a
Topcon 50 IA camera (Tokyo, Japan) coupled to an Image-
Net (Topcon) image digitizing system or a Heidelberg Ret-
ina Angiograph HRA 2 (Heidelberg Engineering Inc).
Autofluorescence was excluded by performing preinjec-
tion fluorescence detection with the highest flash intensity
used for ICGA. At the same time, red-free posterior pole
photographs were taken. Next, a bolus injection was admin-
istered of 500 mg indocyanine green (ICG) (Cardiogreen;
Peaselt, Lorei, Germany) diluted in 7.5 ml of 0.9 % normal
saline. Then, ICGA photographs were taken of the posterior
pole for approximately 2 to 3 min (early phase angiogram).
ICG background fluorescence was analyzed in detail at
12±3 min after the ICG injection (intermediate phase of
angiogram) by taking photographs of the posterior pole and
a minimum of eight frames of the entire periphery (360°).
At the end of the intermediate phase of ICGA, FA was
performed. Early FA frames of the posterior pole were
taken for 2 min. Then, between 4 and 7 min, a 360° pano-
rama image was performed over the periphery (minimum
eight frames); finally, at 10 min, late fluorescein frames
were taken of the posterior pole. Late ICG background
fluorescence was analyzed at 30±4 min after the ICG
injection (late-phase angiogram); this was performed in
the same fashion as that used for the background analysis
of the intermediate phase.
Laser flare assessment was performed with a Kowa FM-
500 (Kowa Company, Ltd., Electronics and Optics Division,
Tokyo, Japan). OCT was performed with an OTI-Spectral
OCT/SLO (OTI Inc., Toronto, Canada) or with a Heidelberg
Spectralis OCT (Heidelberg Engineering Inc.). VF assess-
ments were performed with the G1 program of the OCTOPUS
900 (Octopus 900, G Standard; Haag–Streit International).
The data for every patient was assessed for typical, dis-
colored, birdshot fundus lesions, ICGA dark dots, and FA
evidence of vascular disturbances. The findings were ana-
lyzed and correlated to each other, as described previously
[3]. The fundus score (0–4) was based on the distinctness
and number of discolored lesions. The ICGA score (0–4)
was based on several criteria, including hypofluorescent
dark dots (HDDs), choroidal vessel fuzziness, disk hyper-
fluorescence, and late, diffuse, choroidal hyperfluorescence.
The FA score (0–4) was based on vascular leakage of small
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and large retinal vessels, disk hyperfluorescence, and mac-
ular edema. The data were scored by a blinded investigator
(M.P.). Evaluations were performed at different times, in-
cluding before treatment, after treatment in patients with
disease that had evolved from 1 to 6 years, and after treat-
ment in patients with disease durations over 6 years. The
scores from different times were statistically compared with
a Student’s t-test. The term “at presentation” indicates
when the patient was first seen in our center, not at the
onset of the disease.
Results
Demographics
From 1995 to 2010, 1,268 new patients were examined at
the uveitis clinic at the Center for Ophthalmic Specialized
Care, Lausanne, Switzerland. Of those, 25 patients (2 %; 19
women/6 men, sex ratio 3:1) were diagnosed with BRC.
Nineteen patients had sufficient data to be included in the
study.
The mean age at BRC onset was 49.6±10 years and the
mean diagnostic delay from the onset of symptoms to
diagnosis was 21.5±18 months. The mean follow-up was
85±60 months. All patients were positive for the histocom-
patibility antigen, HLA-A29 (100 %). The mean best-
corrected visual acuity (BCVA) at presentation was
0.84±3.4 in the right eye (RE) and 0.74±3.8 in the left eye
(LE). At last follow-up, the mean BCVA was 0.98±0.25 RE
and 0.92 ±0.36 LE (p was non-significant).
No patient presented with severe hypertension, and for
security purpose five patients with introcular pressure
around 20 mmhg were given treatment with an association
of timolol and dorzolamide (Cosopt®) twice daily.
Anterior segment findings
Anterior inflammatory involvement was very scarce in
BRC. In this study, the mean anterior chamber flare mea-
sured by laser flare photometry in 38 eyes at presentation
with BRC was 8.85±3.36 ph/ms (range 4.7–17.1 ph/ms);
this result implied that laser flare photometry was not a
useful follow-up procedure for BRC. None of the eyes
exhibited iridolenticular synechiae; however, 3/19
(15.8 %) patients exhibited granulomatous keratic precipi-
tates (KPs). Two patients exhibited a single KP in one eye,
and the third patient exhibited two KPs in one eye.
Posterior segment findings
Vitreous cells were present in all 19 patients at presentation.
Cystoid macular edema (CMO) was noted in 14 eyes (39 %)
of eight patients (44 %) at presentation. Oval, depigmented,
birdshot fundus lesions were observed in 16 patients (84 %)
at presentation (Fig. 1). In three patients (16 %), absolutely
no birdshot fundus lesion was detected (Fig. 2). However,
among the seven patients that presented in the initial phase
of the disease (with symptoms for 1 year or less), three
(43 %) exhibited birdshot fundus lesions. In these three
patients, the diagnosis was based on the combined observa-
tions of vitreitis, retinal vasculitis on the FA, typical HDDs
on the ICGA, and a positive HLA-A29 test. Four other
patients had very faint lesions, but none in the peripapillar
area; therefore, those patients would not have been diag-
nosed with BRC based on IRDC criteria, because they did
not fulfill one of the major diagnostic criteria of the IRDC
(depigmented peripapillary oval lesions) [7]. Based on the
IRDC criteria, a total of 7/19 (37 %) patients should not
have been diagnosed with BRC. Papillitis was clinically
present in 15 eyes (39 %) of nine patients (47 %).
Visual field data
Visual field defects were found in at least one eye for all
patients at presentation (100 %). No common characteristic
pattern could be found in the VF defects among these
patients. Moreover, when two defects were observed in the
same patient, the two eyes demonstrated different defect
patterns. The most frequent findings were clusters of rela-
tively moderate defects at the borders of the area explored
(G1 program of the Octopus perimeter) and in the temporal
hemi-field, particularly in the peripapillary area.
At presentation, severe visual field defects were found in
12/38 eyes (32 %) of 7/19 patients (37 %). A visual acuity of
1.0 was noted in 5/38 eyes (13 %) of 3/19 patients (16 %)
due to tubular visual field impairment.
Fluorescein angiography
Among these patients with BRC, a typical feature was
vasculitis in the retinal veins of the arcades, with fuzzy
hyperfluorescence and profuse capillary leakage at the pos-
terior pole and the periphery (Fig. 3). CMO was found in 14/
38 eyes (37 %) of 8/19 patients (42 %), at much less
frequency than previously reported [9–11]. Astonishingly,
in some eyes, despite massive capillary leakage at the pos-
terior pole and the periphery, the macula was devoid of
CMO (Fig. 3). On FA, disc hyperfluorescence was found
in 35/38 eyes (92 %) of 17/19 patients (89 %). The substan-
tial loss of fluorescein from capillaries caused a significant
delay in the impregnation of the large veins; the mean
venous filling time was 42.07±13.1 s. This finding was
previously described by Gass as the arterio-venous circula-
tion delay [12]. However, that interpretation was mislead-
ing, because the arterio-venous circulation time was normal
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on the ICGA, around 18–22 s in all cases (Fig. 4). The
pseudo-arterio-venous delay could be explained by the pro-
nounced loss of fluorescein into the retina due to profuse
capillary leakage; thus, reduced amounts of fluorescein
reached the large veins, and this resulted in a delay in filling
the large veins [13]. In contrast, ICG is a large molecular
complex that does not leak from retinal capillaries; thus, it
showed normal arterio-venous circulation times.
Fig. 1 Typical oval
depigmented birdshot
fundus lesions in a right
and b left eye
Fig. 2 Fundus images of right and left eye of a patient that complained of
blurred vision in the left eye. a The fundus appeared hazy in the affected
eye. No birdshot lesions were visible in either eye. b Fluorescein angio-
graphic image shows venous sheathing compatible with BRC. c
Indocyanine green angiographic image shows typical hypofluorescent
dark dots (HDDs) and fuzzy choroidal vessels, in both (1) the left,
symptomatic eye, and (2) the right eye. These signs strongly suggested
the diagnosis of BRC, and this was confirmed by HLA-A29 positivity
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Fig. 3 Fluorescein angiographic
findings in BRC. Image shows
massive perivascular sheathing
of arcade vessels with massive
leakage from medium-sized ves-
sels and capillary leakage. Note
the CMO on the right side, but
the absence of CMO on the left
side, despite massive leakage.
Note also hyperfluorescent
discs in both eyes
Fig. 4 Pseudo-perfusion delay in BRC. Fluorescein dye showed in-
complete filling of large veins; venous filling required up to 29 min,
1 s. In contrast, ICGA shows complete arterio-venous filling in 23.9 s.
Arrows outline (left frames) incomplete dye filling in FA and (right
frame) fully perfused veins in ICGA
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Indocyanine green angiography (ICGA)
The most constant and consistent finding on ICGA images
was the presence of evenly-sized, round-oval, hypofluores-
cent dark dots (HDDs), regularly distributed over the fundus
in 100 % of cases. In some cases (21 %), these HDDs were
detected only up to the intermediate angiographic time
(8–12 min), which indicated partial-thickness granulomas.
The other 79 % of cases showed HDDs up to the late angio-
graphic time (26–36 min), which indicated large, full-
thickness granulomas, like those observed in VKH disease
[14]. In three patients, the presence of HDDs led to a diagnosis
in the early stage of disease, in the absence of depigmented
oval birdshot lesions (Fig. 2). All cases exhibited fuzzy, indis-
tinct, large, choroidal vessels and late, diffuse, choroidal
hyperfluorescence, but they were much less pronounced than
those described in VKH disease [15]. Disc hyperfluorescence
was only observed in 7/38 eyes (18%) of 4/19 patients (21%).
This rare occurrence indicated much less severe, less acute
choroidal inflammation compared to VKH disease [16]. All
these ICGA signs decreased and/or disappeared after the
introduction of inflammation suppressive therapy. Even the
HDDs disappeared in most cases (57 % of HDDs disappeared
on ICGA after 4 years of immunosuppressive treatment).
Optical coherence tomography (OCT)
Fourteen patients had regular OCT examinations during
follow-up. Intraretinal fluid was detected in 3/4 eyes in the
early stages of disease. During follow-up, the intraretinal
fluid diminished, probably due to therapy. In all seven
patients in the late stage of disease, the retinal thickness
had decreased due to atrophy (100 %); this was concomitant
with the development of thin epiretinal membranes in 13/14
eyes (93 %).
Treatment
Two out of 19 patients had only local treatment; each
received two subTenon’s injections in the predominantly
involved eye, which stabilized the condition. They both
experienced visual field recovery and visual acuity improve-
ments. Follow-up was 12 years in one patient, but only
4 years in the other patient. This indicated that the propor-
tion of patients with a benign evolution could be estimated
as one out of ten. One patient refused treatment, and evolu-
tion was deleterious, with vision of 0.5 OU; the ICGA
demonstrated extensive retinal vasculitis, CMO, papillitis,
and extensive choroidal involvement.
All the remaining patients (16 patients) received at least
two inflammation suppressive treatments. Fourteen patients
received prednisone, beginning with a high dose that was
later tapered. In 11 out of 14 patients, systemic corticosteroid
could be stopped or reduced to less than 10 mg/day. In the
other three patients, the dose was 10 mg/day. Due to diabetes,
two patients received periocular subtenon injections (2–3
injections per eye, given at 1 month intervals) in parallel with
azathioprine in one patient and mycophenolate in the other
patient. The mean duration for systemic therapy was
9.14±4.20 years, which indicated that the disease ran
a severe course in a large proportion of cases.
Table 1 provides an overview of the distribution of spe-
cific immunosuppressive treatments among the 19 patients
in this study.
Evolution of treated patients
At the end of follow-up, visual acuity was 0.98±0.25 in RE
and 0.92±0.36 in LE.
Anterior chamber inflammation remained low, with mean
flare values of 9.14±4.83 ph/ms (range 3.7–18.4 ph/ms) and
the granulomatous KPs had disappeared.
Visual field was recovered in 12/18 patients after 1 year
of treatment. However, 6/18 patients (33 %) (eight eyes)
retained significant visual field defects, with tubular vision
in three patients.
Two patients evolved towards pseudo retinitis pigmen-
tosa fundi, which corresponded to thin, atrophic retinas on
the OCT. In contrast, untreated patients exhibited extensive
exudative retinitis and disc hyperfluorescence.
Angiographic evolution was characterized by a good
response in the choroidal structures on the ICGA. The first
sign of recovery was the disappearance of disk hyperfluor-
escence; then fuzzy vessels were restored, and late hyper-
fluorescence was reduced; finally, the HDDs disappeared.
Response to therapy was less satisfactory in the retina (FA);
there, vasculitis persisted along the veins of the arcades and
capillary leakage was noted in nine out of 11 patients (82 %)
with complete data sets. One patient showed persistence of
retinal disease after 5 years of azathioprine therapy, and
another patient responded well to azathioprine.
Disease evolution during treatment was analyzed with an
arbitrary, masked, scoring system (0–4) [3]. This accounted
Table 1 Distribution of immunosuppressive treatments among 18
patients with BRC; most patients required two drugs for adequate
treatment
Drug Number of patients
Prednisone 14
Azathioprine 10
Cyclosporine 5
Anti-TNF 2
Mycophenolate mofetil 5
IV Immunoglobulines 1
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well for the evolutionary pattern of increasing fundus
lesions over time. Retinal disease remained persistent, but
choroidal involvement responded well to treatment. How-
ever, when patients were examined early and received early
treatment, the retinal disease also responded well to therapy
(Table 2, Fig. 5).
Discussion
BRC is a rare disease, and investigations essential for
diagnosis, like VF testing and ICGA, have still not been
established as routine, or they are not reported. There-
fore, BRC appraisal has remained incomplete, and mis-
conceptions have found their way into ophthalmic
literature.
We studied 19 patients that had received, in addition to
the classical work-up, laser flare photometry, choroidal
assessments, and VF testing, both at presentation and upon
follow-up. The aim of this study was to rectify some of the
misconceptions that currently surround BRC, and to miti-
gate the risk of having misconceptions perpetuated in future
articles and textbooks.
Birdshot retinochoroiditis occupies a special place in
intraocular inflammatory conditions, because the choroid
and retina are both primary targets for inflammatory insults.
Both structures are consistently but independently, involved
in the inflammatory process. In contrast, two other condi-
tions, tuberculous chorioretinitis and sarcoidosis, also in-
volve inflammation of the retina and choroid, but these
structures are affected randomly, not systematically, as in
BRC [17, 18].
Moreover, most intraocular inflammatory conditions af-
fect one primary target, and the neighboring structures are
only secondarily involved. For example, in VKH disease,
the inflammatory reaction is directed towards the choroidal
melanocytes. It remains unknown why, in BRC, inflamma-
tion is generated simultaneously and systematically both in
the retina and the choroid.
Until 15 years ago, only retinal involvement was detect-
able with angiographic examination, which did not enable
global analysis of intraocular inflammation [19]. Currently,
the availability of ICGA has enabled analyses and monitor-
ing of choroidal inflammatory involvement; thus, precise
appraisal of both retinal and choroidal inflammation can
be performed in parallel [8, 14, 17, 20, 21].
ICGA has represented a major improvement in the inves-
tigation of BRC, because it has revealed the importance of
choroidal disease [17]. With ICGA, it was discovered that
BRC exhibited a particular inflammatory pattern, where
both the choroid and the retina were independent targets
and sites of inflammation. This contrasted with the pattern
of most uveitides, where inflammation typically originated
in one structure or point, and inflammation in surrounding
structures only occurred with disease progression [22].
The improved morphological appraisal of disease activity
provided with dual fluorescein and ICGA has enabled cor-
relations of morphological findings with functional loss.
Thus, it has been possible to identify the diseased structures
underlying functional loss. In fact, over 10 years ago, sev-
eral groups reported extensive retinal inflammation, which
was most likely the cause of visual field defects found in
100 % of cases; however, to date, this finding has remained
largely unrecognized [4–6, 23].
Table 2 Evolutionary profile of
depigmented oval birdshot fundus
lesions, fluorescein angiography
(FA), and indocyanine green an-
giography (ICGA) over time
Subgroups Depigmented birdshot
fundus lesions (score)
FA score ICGA score
Group 1: non-treated
< 1 year duration 1.03±0.84 2.19±1.15 3.0±0.65
Group 2: treated
1–7 years’ duration 2.75±0.8 2.5±0.97 2.9±0.57
Group 3: treated
> 7 years’ duration 2.95±0.79 2.3±0.57 0.8±0.27
P: 1 versus 2 p<0.0005 p0ns p<0.05
P: 1 versus 3 p<0.002 p0ns p<0.00001
P: 2 versus 3 p0ns p0ns p<0.02
Fig. 5 Evolution of fundus lesions, FA signs, and ICGA signs over time
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We previously established a scoring system to rate the
severity of fundus lesions, based on FA and ICGA signs.
With this scoring system, we showed that the deleterious
functional evolution (visual field) observed in many BRC
cases was due to persistent retinal disease [24], because the
retinal system was less responsive to therapy than the cho-
roidal system. This might be explained by differences in
accessibility to the choroidal and retinal systems. The cho-
roid is readily treated with systemic therapy through the
choriocapillaris fenestrations; in contrast, the retina is more
difficult to access due to blood–ocular barriers, and hence,
treatment is less efficacious. On the other hand, reports are
scarce on choroidal disease in BRC [3, 25–27].
The choroidal ICGA lesions (dark dots) were originally
attributed to choroidal granuloma; but this hypothesis had
remained conjectural until histopathological sections of the
choroid from a patient with BRC had become available. The
histopathology clearly showed partial-thickness granulomas
in the choroidal stroma [28]. In contrast to retinal disease,
choroiditis readily responds to inflammation suppressive
therapy; a large proportion of HDDs regress with therapy.
Nevertheless, typical, oval, depigmented birdshot lesions
remain apparent, unless treatment is given early [17]. The
genesis of the typical oval birdshot fundus lesion has also
been conjectural, but histopathological data are available
that show a granulomatous reaction against islets of stromal
melanocytes. Those data have supported the hypothesis that
the birdshot lesions represent areas that lack melanocytes
after resolution of the granulomas [29].
Importantly, early diagnosis of BRC is only possible with
ICGA, because choroidal disease is occult, and, in the
absence of birdshot lesions, the typical choroidal HDDs
can only be detected with ICGA.
The availability of histopathological sections has shown
that BRC has granulomatous features [28]. Therefore, it is
not surprising that, rarely, granulomatous KPs have been
found. Although it occurs rarely, the presence of KPs should
not be considered an exclusion criterion, as stated a few
years ago in the article on research diagnostic criteria for
birdshot chorioretinopathy [7]. The same article minimized
the value of HLA-29 as a strong diagnostic element. Our
study confirmed that HLA-29 is one of the most specific and
sensitive diagnostic tests for BRC, when it is performed in
the presence of a compatible clinical background. The fre-
quency of HLA-A29 antigen in a Caucasoid population is
5.7 %; in an oriental population, the frequency is only
0.8 %. The relative risk for developing BRC is 224× higher
in patients positive for the HLA-A29 antigen.
Another misconception generated from older publica-
tions, which should be corrected, was that BRC is a benign
disease [29]. Only two of our patients exhibited a benign
course. After excluding the patient that refused treatment, all
our patients required at least two immunosuppressive drugs.
Moreover, our data suggested that we should be prepared
for prolonged therapy. All systemically treated patients
remained on low-dose maintenance therapy at the end of
follow-up, and the mean treatment duration was over
9 years. In one patient, discontinuation of azathioprine
therapy was attempted after 8 years, but a recurrence oc-
curred 9 months later, with changes in vision and worsen-
ing of FA signs. Treatment was reintroduced with a short
course (8 weeks) of oral prednisone and parallel reintro-
duction of azathioprine; this stabilized the disease. Our
group achieved a favorable outcome with early, sustained,
high-dose immunosuppressive therapy.
Considering the results from all investigations on the
different compartments of the eye, including the choroid,
we have gained a fairly clear, rectified depiction of BRC.
We know that BRC is a granulomatous, inflammatory dis-
ease associated with HLA-A29 antigen in nearly 100 % of
cases. Inflammation develops independently, but simulta-
neously, in the retina and choroid. At the beginning, choroi-
dal involvement is occult, and it can only be detected with
ICGA. At clinical presentation, 100 % of cases exhibit
visual field changes linked to retinal disease. Evolution is
severe in over 90 % of cases, and adequate treatment
requires 2–3 immunosuppressive agents for prolonged peri-
ods. Choroidal disease will readily respond to systemic
inflammation suppressive therapy, as evidenced by normal-
ization of ICGA findings. Depigmented birdshot lesions are
thought to result from the destruction of melanocytic, stro-
mal islets by the granulomatous process, and the lesions
later disappear, indicated by ICGA. Retinal inflammatory
involvement is less responsive to therapy, and it is responsible
for deleterious evolution, which cannot be prevented in some
cases. Ultimately, the retina often becomes atrophic, as
evidenced by OCT, and pseudoretinitis pigmentosa may occur.
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